DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients.
Phase of Trial: Phase IV
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DAPAMAAST
- Sponsors AstraZeneca
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 17 Oct 2019 Planned End Date changed from 31 Dec 2019 to 8 Nov 2019.
- 17 Oct 2019 Planned primary completion date changed from 31 Dec 2019 to 8 Nov 2019.